» Articles » PMID: 10411546

Rapid Generation of Broad T-cell Immunity in Humans After a Single Injection of Mature Dendritic Cells

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1999 Jul 20
PMID 10411546
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that initiate protective T-cell immunity in mice. To study the immunogenicity of DCs in humans, we injected 9 healthy subjects subcutaneously with a control injection of autologous monocyte-derived, mature DCs, followed 4-6 weeks later by DCs pulsed with keyhole limpet hemocyanin (KLH), HLA-A*0201-positive restricted influenza matrix peptide (MP), and tetanus toxoid (TT). Four more subjects received these antigens without DCs. Injection of unpulsed DCs, or antigens alone, failed to immunize. Priming of CD4(+) T cells to KLH was observed in all 9 subjects injected with KLH-pulsed DCs, and boosting of TT-specific T-cell immunity was seen in 5 of 6 subjects injected with TT-pulsed DCs. Injection of antigen-pulsed DCs led to a severalfold increase in freshly isolated MP-specific, IFN-gamma-secreting CD8(+) T cells in all 6 HLA-A*0201-positive subjects, as early as 7 days after injection. When T cells were boosted in culture, there was an increase in MHC tetramer-binding cells and cytotoxic T cells after DC vaccination. These data provide the first controlled evidence of the immunogenicity of DCs in humans, and demonstrate that a single injection of mature DCs rapidly expands T-cell immunity.

Citing Articles

Dendritic cell vaccine of gliomas: challenges from bench to bed.

Zheng Y, Ma X, Feng S, Zhu H, Chen X, Yu X Front Immunol. 2023; 14:1259562.

PMID: 37781367 PMC: 10536174. DOI: 10.3389/fimmu.2023.1259562.


Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.

Robinson M, Villa N, Jaye D, Nooka A, Duffy A, McCachren S J Clin Invest. 2023; 133(15).

PMID: 37526080 PMC: 10378152. DOI: 10.1172/JCI167629.


Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.

Takei J, Kamata Y, Tanaka T, Fukasawa N, Gomisawa K, Satake M Cancer Immunol Immunother. 2023; 72(10):3175-3189.

PMID: 37382632 PMC: 10491709. DOI: 10.1007/s00262-023-03482-8.


A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.

Dasyam N, Sharples K, Barrow C, Huang Y, Bauer E, Mester B Cancer Immunol Immunother. 2023; 72(7):2267-2282.

PMID: 36881133 PMC: 10264280. DOI: 10.1007/s00262-023-03400-y.


Next-generation antigen-presenting cell immune therapeutics for gliomas.

Lee-Chang C, Lesniak M J Clin Invest. 2023; 133(3).

PMID: 36719372 PMC: 9888388. DOI: 10.1172/JCI163449.


References
1.
Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N . A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood. 1997; 90(9):3640-6. View

2.
Ridge J, Rosa F, Matzinger P . A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998; 393(6684):474-8. DOI: 10.1038/30989. View

3.
Lalvani A, Brookes R, Hambleton S, Britton W, Hill A, McMichael A . Rapid effector function in CD8+ memory T cells. J Exp Med. 1997; 186(6):859-65. PMC: 2199056. DOI: 10.1084/jem.186.6.859. View

4.
Zhou L, Tedder T . CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A. 1996; 93(6):2588-92. PMC: 39841. DOI: 10.1073/pnas.93.6.2588. View

5.
Wen Y, Ling M, Bailey-Wood R, Lim S . Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998; 4(4):957-62. View